SARS-CoV-2 Neutralizing Antibody ELISA Kit

With the demand for vaccine development, Creative Diagnostics have developed two ELISA kits for qualitative detection of SARS-CoV-2 neutralizing antibody in serum and plasma.

Product Lists:

Kits Features

• The detection of SARS-CoV-2 neutralizing antibodies offers important information for evaluating immune responses to COVID-19. It has multiple applications such as studies of human immunity and vaccine development among others.
• CD’ SARS-CoV-2 Neutralizing Antibody ELISA Kit functions as a simple, qualitative indicator of positive or negative samples. Disease-free positive and negative plasma controls are supplied to confirm the assay is performing as expected.
• The format of our ELISA (in which neutralizing antibodies must recognize the SARS-CoV-2 spike receptor binding domain to inhibit ACE2 binding) provides an efficient and effective screening tool for determining functional antibody neutralization capabilities.
• The entire detection process takes about 80 minutes, while traditional neutralization experiments require cell culture, which usually takes 2-3 days to complete the test.
• Since a sterile environment is not required, the detection operation can be performed under general experimental conditions, which is more convenient.

Antigens and Antibodies for COVID-19 Neutralizing Antibody Assays

Assay Formats

Our competitive assay format measures neutralizing antibodies of the SARS-CoV-2 spike RBD and ACE2 interaction in human plasma and serum. For DEIASL055, recombinant human ACE2 receptor protein is immobilized on the plate, followed by the addition of neutralizing antibody or HRP labelled RBD. This interaction is then detected by reading absorbance at 450 nm. The interaction between SARS-CoV-2 spike RBD and ACE2 is disrupted in the presence of neutralizing antibodies in the sample, preventing signal emission (Figure 1). For DEIA-WZ021, recombinant RBD protein is immobilized on the plate instead of human ACE2 and HRP labelled recombinant human ACE2 is added into the plate to competitive with neutralizing antibody (Figure 2). This assay format allows for the detection of all neutralizing antibodies independent of isotype, including IgA, which is particularly salient to mucosal tissue infections.

Figure 1. Assay Principle of Creative Diagnostics SARS-CoV-2 Neutralizing Antibody ELISA Kit (CD Cat# DEIASL055)

Figure 2. Assay Principle of Creative Diagnostics SARS-CoV-2 Neutralizing Antibody ELISA Kit (CD Cat# DEIA-WZ021)

Introduction

Since the outbreak of the new coronavirus pneumonia (Corona Virus Disease 2019, COVID-19), it has rapidly swept across most countries around the world and is still spreading. To deal with the epidemic, it is very urgent to successfully develop a safe and effective vaccine. According to the data released by the WHO a few days ago, there are 198 candidate new coronavirus vaccines being developed and registered in various countries, of which 44 have entered the clinical trial stage, and 10 have entered the phase III clinical trial. In the process of vaccine development and marketing, the presence of neutralizing antibodies can indicate an ability to suppress progression of SARS-CoV-2 infection and is important in evaluating the lifetime and efficacy of specific antibodies in the host.

Related Products:

SARS-CoV-2 Neutralizing Antibodies

Pseudotyped VSV-SARS-CoV-2 Spike

Staphylococcal Enterotoxin from Staphylococcus aureus

Phospholipase A2 receptor (PLA2R) and THSD7A stable cell line

Antigens and Antibodies for CHIKV

Respiratory Syncytial Virus Antigens and Antibodies for Vaccine Development

Pharmacokinetics ELISA Kits

Twitter Facebook